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Ebola is a single-stranded ribonucleic acid (RNA) virus that has become one of the most feared and virulent pathogens, affecting 
both humans and great apes. Within a few days, the 
virus induces acute fever and very often death, and is 
usually associated with haemorrhagic syndrome in up 
to 90% of symptomatic individuals.1,2 Five species of 
the genus Ebolavirus are known: Bundibugyo, Sudan, 
Zaïre, Reston and Taï Forest. The Reston species does 
not cause human fatalities, although it kills non-
human primates such as chimpanzees and monkeys, 
as well as other animals like duikers.1–3 Whilst Ebola 
is endemic in regions of Central and West Africa and 
the Philippines, outbreaks are usually characterised 
by widespread fear, exacerbated by worldwide media 
hype and concern for the international spread of the 
virus, including via potential bioterrorism by dissident 
groups around the world.2,4
Generally, the disease process is defined by rapid 
immune suppression and a systemic inflammatory 
response that leads to vascular, coagulation and 
immune system impairment. Increasingly, this 
impairment results in multi-organ and multisystem 
failure and shock, causing death. Current treatment 
is supportive; disease management and containment 
efforts undertaken in communities and healthcare 
institutions focus mainly on minimising the further 
spread of the epidemic while restoring calm.3,5 The 
haemorrhagic syndrome associated with the viral 
infection results in a high rate of case fatalities largely 
because there is no specific and approved post-
exposure treatment or a vaccine.1,2 However, various 
studies conducted on animal models have shown 
promising results using agents that interfere with the 
viral RNA and glycoprotein spikes.2,4,6 
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abstract: The Ebola virus is a highly virulent, single-stranded ribonucleic acid virus which affects both humans 
and apes and has fast become one of the world’s most feared pathogens. The virus induces acute fever and death, 
with haemorrhagic syndrome occurring in up to 90% of patients. The known species within the genus Ebolavirus 
are Bundibugyo, Sudan, Zaïre, Reston and Taï Forest. Although endemic in Africa, Ebola has caused worldwide 
anxiety due to media hype and concerns about its international spread, including through bioterrorism. The high 
fatality rate is attributed to unavailability of a standard treatment regimen or vaccine. The disease is frightening 
since it is characterised by rapid immune suppression and systemic inflammatory response, causing multi-organ 
and system failure, shock and often death. Currently, disease management is largely supportive, with containment 
efforts geared towards mitigating the spread of the virus. This review describes the classification, morphology, 
infective process, natural ecology, transmission, epidemic patterns, diagnosis, clinical features and immunology 
of Ebola, including management and epidemic containment strategies.
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امللخ�ص: فريو�ض ايبوال هو فريو�ض �سديد اخلطورة من فئة احلم�ض النووي الريبي اأحادي الطاق والذي ي�سيب الب�رش والقرود واأ�سبح 
ب�رشعة اأحد اأكرث االأمرا�ض املقلقة عامليًا. الفريو�ض يوؤدي اإىل احلمى احلادة والوفاة مع متالزمة النزف يف حواىل %90 من املر�سى. 
االأنواع املعروفة من جن�ض فريو�ض ايبوال هي بنديبيجيوا، ال�سودان، زائري، ري�ستون، وتي فور�ست. بالرغم من توطنة يف افريقيا، اأحدث 
ايبوال قلق عاملي ب�سبب ال�سجيج االإعالمي واخلوف من االأنت�سار الدويل مبا يف ذلك من خالل االإرهاب البيولوجي. اأرتفاع االإماتة يعود 
اإىل عدم وجود نظام عالجي ر�سمي اأو حت�سني. يعترب املر�ض خميف لتميزة ب�رشعة الكبت املناعي واأ�ستجابة التهاب املجموعة، والذي 
يوؤدي اإىل ف�سل النظام وجمموعة االأع�ساء، ال�سدمة ويف كثري من االأحيان املوت. حاليًا، عالج املر�ض هو الدعم اإىل حد كبري، مع جهود 
االإيكولوجية،  الطبيعة  العدوى،  طريقة  املورفولوجيا،  ايبوال،  طراز  ت�سف  املراجعة  هذة  الفريو�ض.  اأنت�سار  تهوين  نحو  موجهة  اأحتواء 
االنتقال وت�سنيف التوطني، والت�سخي�ض، املظاهر ال�رشيرية وعلم املناعة، مبا يف ذلك العالج واأ�سرتاتيجيات احتواء التوطني.   
مفتاح الكلمات: حمى نزفية، اإيبوال؛ فريو�ض ايبوال؛ نزف؛ فريو�سات خيطية؛ العوامل االإمرا�سية؛ الفوعة؛ عالج االأمرا�ض.
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in length, with some as long as 14,000 nm. Structurally, 
Ebola viruses consist of three layers: a surface 
glycoprotein layer, a lipid membrane envelope unit 
and an internal tubular helical nucleocapsid.4,9 The 
virus surface layer consists of glycoprotein spikes, each 
about 7–10 nm long, spaced at about 10 nm intervals. 
These spikes aid the entry of the virus into host 
cells by specifically acting as mediators for receptor 
binding and cell membrane fusion. The second layer, 
the lipid membrane, surrounds the internal helical 
nucleocapsid. This, in turn, houses the third layer, the 
negative-stranded viral genome, which controls viral 
replication in cells.4,8,9
Infection of Host Cells and 
Replication 
Ebola viruses infect different cell types, including 
macrophages, fibroblasts, hepatocytes and endothelial 
cells, mediated by the glycoprotein spikes that play an 
important role in endocytosis, a process vital for the 
entry of the virus into host cells. When an Ebola virus 
enters the host cells, viral replication starts, resulting 
in numerous new virus particles.9,10 The process 
of viral replication is mediated by the synthesis of a 
positive RNA strand that serves as a template for the 
production of additional viral genomes. As replication 
continues, the new viruses continually bud off, 
attaining their outer lipid membrane from the host cell 
membrane, killing them instantly.1,7 As more and more 
host cells rupture due to the budding of new viruses, 
cascades of reactions are triggered, resulting in the 
lethal Ebola haemorrhagic fever (EHF) syndrome.1,4,7
Ecology and Distribution
EHF is considered a classical zoonosis because of its 
ability to be transmitted naturally from vertebrate 
animals to humans and other mammalian species.4,11 
Despite the fact that non-human primates have 
repeatedly been a source of infection for humans, 
the natural reservoir of the Ebola virus still remains 
unknown, although bats have been repeatedly impli-
cated as being a natural reservoir of filoviruses.4,5,11,12 
This declaration followed the detection of viral 
RNA and antibodies in three specific bat species—
Hypsignathus monstrosus, Epomops franqueti and 
Myonycteris torquata—implying that these bats 
could be natural reservoirs.11,12 The claim that bats 
play a central role in Ebola transmission followed 
the discovery that bats infected experimentally did 
not die.13 This claim received further support when 
laboratory observations in Uganda confirmed that 
The objective of this integrated review is to describe 
the classification, morphology, infective process and 
natural ecology of Ebola, as well as the transmission 
and epidemic patterns of the virus. This review also 
details the diagnosis, clinical features and immunology 
of the virus, including current disease management 
practices and epidemic containment strategies. A 
literature review was conducted of peer-reviewed, 
original research and review papers indexed in 
PubMed, CINAHL, MEDLINE, Scopus, ScienceDirect 
and Google Scholar databases and published between 
January 1990 and October 2014. Selected medical 
textbooks and online resources that addressed specific 
aspects related to the Ebola and Marburg viruses were 
also consulted. Searches were conducted using the 
following search terms: ‘viral haemorrhagic fevers’, 
‘Ebola virus disease’, ‘Filoviridae infection’, ‘ecology’, 
‘epidemics’, ‘epidemiology’, ‘diagnosis’, ‘signs and 
symptoms’, ‘immunology’ and ‘disease management’ 
in various combinations, in order to retrieve articles 
published in English that addressed various aspects of 
Ebola virus disease (EVD). 
Classification and Taxonomy 
The Ebola virus is classified as a biosafety risk group 
4 agent, which is the highest rating on the biosafety 
scale, due to the high health risk it poses for laboratory 
personnel and the public.3 Ebola virus is a lipid-
enveloped, single-stranded, negative-sense RNA 
virus belonging to the genus Ebolavirus in the family 
Filoviridae and order Mononegavirales.4,7 Ebola and 
Marburg viruses are the only filoviruses that cause 
severe haemorrhagic fever syndrome in humans 
and non-human primates such as monkeys and 
chimpanzees.5,8 The Marburg virus consists of only 
one strain while the genus Ebolavirus comprises five 
species, which are named after the country or location 
in which they were first discovered.1,2,5,7 The four 
species Zaire ebolavirus, Sudan ebolavirus, Taï Forest 
ebolavirus (formerly Cote d'Ivoire ebolavirus) and 
Bundibugyo ebolavirus occur in sub-Saharan Africa, 
whereas the fifth strain, Reston ebolavirus, originated 
from the Philippines, although it was first isolated in 
Reston, Virginia, USA. 
Morphology 
In their innate states, Ebola viruses exist as filamentous 
and pleomorphic structures, often taking on different 
shapes. They may occur in long filaments or branched, 
U-shaped, 6-shaped or circular forms.1,4 Ebola viruses 
have a uniform diameter of 80 nm but vary considerably 
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African fruit bats (Rousettus aegyptiacus) infected 
naturally with filoviruses looked healthy and did not 
show any signs of illness, despite testing positive 
for Marburg virus isolates and yielding live viruses 
from liver and spleen tissue samples.14 This further 
supports the claim that these bats could harbour 
filoviruses in between outbreaks.4,15 These findings 
corroborate reports of studies conducted in Gabon 
and the Democratic Republic of Congo (DRC), which 
concluded that bats of the order Chiroptera, among 
them the African fruit bats of the family Pteropodidae 
and species R. aegyptiacus, naturally host the Ebola 
and Marburg viruses.11,12,15 
Despite these various investigations, to date none 
of the Ebola virus strains have ever been isolated from 
naturally infected animals. What is certain though, is 
that the virus is endemic in rain forests of Africa and 
the Philippines and, like humans, non-human primates 
also become infected directly from as yet unknown 
natural reservoirs.4,5,16 
Modes of Transmission
The primary mode of Ebola transmission from a natural 
reservoir to humans or primates remains unknown, 
although most outbreaks appear to be zoonotic.3–5 
However, despite being zoonotic, filoviruses are 
neither spread continuously from person to person 
nor do they remain latent in primates.11,15,16 The 
main secondary mode of transmission from person 
to person is nosocomial and starts by contact with 
blood and body fluids from an infected person. 
Infection then occurs through direct inoculation from 
contaminated instruments and infected droplets via 
mucous membranes or after humans have handled 
infected primates.1,3,5 
In hospitals, health workers may become infected 
through close contact with patients, especially 
when they do not use proper infection prevention 
precautions or barrier nursing techniques.2,3,16 In 
community settings, funeral rituals are a key way in 
which the virus spreads, particularly where there is 
direct physical contact while performing cultural 
rituals like shaving and bathing the deceased.3,5,17 
Infected humans become contagious after developing 
early signs and symptoms of the disease—particularly 
a high fever and headache. Generally, larger Ebola 
outbreaks tend to occur after infected patients 
enter healthcare systems where barrier nursing and 
epidemic control practices are inadequate.2,3,5
Clinical Manifestations 
Clinically, EHF or EVD, which is the human disease 
caused by any of the five Ebola virus strains, present 
with a sudden onset of signs and symptoms following 
an incubation period of two to 21 days.1,3,5 The initial 
signs and symptoms include a severe frontal headache 
radiating to the occipital region, acute fever exceeding 
39 °C, general weakness, incapacitation, cervical and 
lower back pain and pains of the large joints.3–5 On 
physical examination, Ebola patients typically look very 
sick and are often lethargic, presenting frequently with 
a ‘ghost face’, (i.e. an expressionless face with deep-set 
eyes). These signs and symptoms are followed by rapid 
and severe weight loss due to the loss of appetite, and 
dysphagia resulting from very painful throat lesions 
and severe disease symptoms.16,18,19 
After two to three days, patients begin to 
experience gastrointestinal symptoms, including 
severe, cramping abdominal pain; haematemesis or 
vomiting blood; nausea, and bloody diarrhoea.2,3,5 By 
the fourth day, patients frequently experience a severe 
sore throat, commonly perceived as a ‘lump’ in the 
throat, further worsening the dysphagia.4,16,18 By the 
fifth day, patients present with conjunctivitis, chest 
pain, coughing, shortness of breath, nasal discharge, 
dehydration and haemorrhagic symptoms, which may 
vary from melaena (dark-brown bloody stool) to a 
slow overt oozing of blood from the gums in severe 
cases.3–5
After six to eight days, there is involvement of the 
central nervous system, manifested by somnolence, 
delirium and coma.3–5 There is also severe metabolic 
disturbance and diffuse coagulopathy.4,9 This period 
also marks a bimodal peak of the prognostic disease 
pattern, characterised by a binary phenomenon where 
patients either markedly improve or deteriorate 
further and then die from multiple organ and system 
failure and shock.18,20
In non-fatal cases, the symptoms are generally 
less severe, except that the fever persists for several 
days. These patients begin to show impressive signs of 
recovery typically at the turn of the first week, a period 
associated with the appearance of a humoral antibody 
response.4,9 However, in fatal cases, the clinical picture 
is more acute with signs and symptoms appearing early 
in the first week.4,9 As the week progresses, severely sick 
patients may bleed from the nose, gums, vagina, anus, 
urethra and injection sites and may even experience 
the overt vomiting of blood.3–5 Other patients develop 
a pruritic, generalised maculopapular rash, jaundice, 
tinnitus, haematuria, vertigo, amenorrhoea, oliguria, 
hiccoughs and lymphadenitis.4,16,19 Many severely 
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rapid, high-level, immunological response targeting 
the viral glycoprotein coat is thought to lead to patient 
survival.4,22 This observation is based on the findings 
of studies conducted on survivors of the 1996 Ebola 
outbreak in Gabon, which concluded that an early 
immune response appeared to be key to surviving an 
Ebola infection.4,22,23 
In the early stages of infection, survivors tend 
to produce increased levels of IgG and IgM, which 
target the viral coat and are associated with a strong 
inflammatory response, including interleukin β, 
interleukin 6 and tumour necrosis factor-α. This is 
followed by clearance of circulating viral antigens 
and sustained activation of the cytotoxic T cell 
pathway.4,22–24 Studies further show that patients who 
die of Ebola have higher concentrations of interferon-γ 
and their peripheral blood cells show more extensive 
apoptosis (programmed cell death) compared to that 
of survivors.4,24 Early and well-regulated inflammatory 
responses characterised by low levels of interferons 
and reactive oxygen and nitrogen species indicate 
higher chances of recovery from Ebola.4,25 
In contrast, a defective antibody response 
associated with increased blood concentrations of 
nitric oxide, resulting from an inappropriate response 
to the virus particles, is associated with death.4,21 
Similarly, studies on serial plasma indicate that survival 
appears to be related to orderly and well-regulated 
humoural and cellular responses.26 These findings 
suggest that impaired humoral responses with absent 
specific IgG and barely detectable IgM seem to indicate 
failure to control virus replication, thus leading to 
death.25,26 These findings imply that the absence of a 
vigorous immune response and lymphopaenia, or low 
levels of T cells due to an ineffective immunological 
response, characterise individuals who do not 
survive Ebola.4,26,27 These studies further suggest that 
both cellular and humoral responses are essential in 
protecting patients against Ebola infection. In the 
same way, the levels of immunological response that 
patients generate determine whether they will survive 
or succumb to EVD.
Therapeutic Interventions and 
Vaccination 
While several candidate treatment options are being 
tested, no specific chemotherapeutic or immunisation 
strategy yet exists for Ebola.2,6,27 The danger posed 
by Ebola has been compounded by the discovery of 
newer virus strains and the existence of Ebola virus 
antibodies in fruit bats in Bangladesh, which extends 
the horizon of future Ebola infection far beyond 
ill patients will also develop hepatosplenomegaly, 
pancreatitis and facial oedema, and typically die 
between day six and 16 due to multiple organ and 
system failure and hypovolemic shock.3,4,9 
In patients who survive, recovery is slow, usually 
lasting several weeks to several months, and is 
associated with severe incapacitation, weight loss, a 
persistent headache, poor appetite, body weakness 
and a reduced libido (among other symptoms). 
Survivors may also experience psychotic disturbances 
that typically last between three and nine months after 
the infection, characterised by episodes of mental 
confusion, anxiety, fatigue, depression, restlessness and 
aggressiveness.3–5,9 In pregnant women, miscarriages 
are common and clinical findings suggest an increased 
risk of death among the children of infected mothers, 
possibly due to transmission of the Ebola virus to 
their babies, either through breast milk or by direct 
maternal contact.4,5,9
Diagnostic Criteria 
Clinical diagnosis of EVD is indicated after the 
occurrence of clusters of cases with prodromal 
fever, bleeding tendencies and person-to-person 
transmission, which is frequently associated with 
prostration, lethargy, wasting, diarrhoea and skin 
rashes.2–4 Laboratory diagnosis of EVD may be 
confirmed using acute-phase serum by measuring 
the level of the specific immunological response 
or by detecting viral antigens and genomic RNA 
or isolating viruses.3,5,9 Immunoglobulin M (IgM) 
and immunoglobulin G (IgG), the antibodies 
formed against EVD, can be measured using an 
immunofluorescence assay (IFA), immunoblot or 
enzyme-linked immunosorbent assay (ELISA).2,3,5 
The viral antigen and genomic RNA may also be 
detected using immunohistochemistry, IFA, ELISA 
and reverse transcription-polymerase chain reaction 
techniques.2,3,5 Direct detection of virus particles 
may be undertaken using electron microscopy.3–5 
However, as a general rule and to ensure safety, it is 
vitally important that all laboratory diagnoses occur 
only in biosafety level 4 facilities, ensuring maximum 
biological containment. This is in order to reduce the 
risk of infection of laboratory personnel.3–5
Immunological Response
Humoral response to Ebola viruses can be detected 
as early as 10–14 days after infection. The specific 
antibodies formed against the viruses are directed 
primarily against the viral surface glycoproteins.4,21 A 
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Africa and the Philippines.2,4,12 Although no specific 
therapy exists, convalescent serum has been used in 
critical situations. This was the case during the 1995 
Zaire ebolavirus outbreak in Kikwit, DRC, when eight 
Ebola patients received blood transfusions from Ebola 
survivors, seven of whom recovered.28 In the current 
outbreak in West Africa, an experimental serum has 
been successfully used to treat five medical workers—
two Americans and three West Africans—following 
approval by a World Health Organization panel of 
experts.29 The sixth recipient, a Spanish priest, died 
despite receiving ZMapp™, the experimental drug 
being co-developed by Mapp Biopharmaceutical, 
Inc. (San Diego, California, USA) and Defyrus, Inc. 
(Toronto, Canada).30 
The ZMapp™ experimental drug is classified 
as a humanised monoclonal antibody, harvested 
from the serum of Ebola-infected mice with major 
components produced in the Nicotiana benthamiana 
strain of tobacco. The drug works by attacking specific 
proteins on the surface of the Ebola virus, thereby 
reducing its virulence.29,30 Another drug currently 
undergoing human testing is TKM-Ebola, which 
has been developed by Tekmira Pharmaceuticals 
Corp. (Burnaby, British Columbia, Canada). TKM-
Ebola is a systemically delivered, small interfering 
RNA therapeutic that is administered using novel 
lipid nanoparticle delivery technology. TKM-Ebola 
interrupts the genetic coding of the Ebola virus 
by blocking the expression of the L proteins of the 
RNA polymerase of the Ebola virus, thus hampering 
replication of the virus within the host cells.31
Since there is still no specific therapy in response to 
EVD, the most appropriate treatment during outbreaks 
is supportive therapy. This involves balancing patients’ 
electrolytes, maintaining optimal oxygenation and 
blood pressure levels and ensuring their adequate 
nutrition and comfort.3,5,32 In addition, there should be 
prompt treatment of any complications such as super-
infections and dehydration to prevent cardiovascular 
collapse and renal insufficiency.32 Further, it is 
recommended that while providing this supportive 
therapy, caregivers should adhere to strict barrier 
nursing practices, which are characterised by careful 
handling of blood and body fluids. Finally, it must be 
ensured that deceased individuals are buried promptly 
in order to prevent transmission of the virus to others. 
Conclusion
Ebola virus infection, and the haemorrhagic 
syndrome that ensues, leads to a high rate of case 
fatalities largely due to the lack of specific post-
exposure prophylactic treatments or a vaccine. The 
disease process is characterised by rapid immune 
suppression and multisystem involvement, leading to 
the impairment and eventual collapse of various organs 
and systems, and resulting in hypovolemic shock and 
death. Current patient management practices mainly 
involve supportive care, including meeting patients’ 
needs for hydration, electrolyte balance, nutrition and 
comfort. This care should be provided in designated 
health facilities with isolation units so as to limit the 
further spread of the Ebola virus. In summary, in the 
absence of specific treatments, the most cost-effective 
outbreak management and containment interventions 
are preventative in nature and are largely aimed at 
breaking the human-to-human infection transmission 
cycle at both institutional and community levels. These 
measures include early case identification, patient 
isolation, use of personal protective equipment and 
safe burial procedures, as well as on-going community 
education and mobilisation.
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